To investigate the biochemical signature in the eight transitioning patients, the same CP model was used to predict their MS phenotypes, Figure 2C. Utilizing the significance threshold of 6% derived from Figure 2A, three of the transitioning patients are predicted as PMS with single-label predictions (T1-T3). The gene discussed is CP; the disease is myeloid sarcoma.